文献速递胸部肿瘤

IASLC pN2非小细胞肺癌残留肿瘤描述符验证研究

A Validation Study of the Recommended Change in Residual Tumor Descriptors Proposed by the International Association for the Study of Lung Cancer for Patients With pN2 NSCLC.
PubMed 文献 · J Thorac Oncol · 2021-02-16

该研究回顾性分析了2004至2018年接受解剖性切除的1039例pN2 NSCLC患者,比较UICC与IASLC残留肿瘤(R)分类的预后意义。IASLC标准将大量UICC R0患者重新分类为R(un)或R1/2,且IASLC R(un)预后介于R0与R1/2之间,提示IASLC R描述符可优化分期并指导辅助治疗决策。

要点

  • IASLC标准使UICC R0患者中21.8%重分类为R(un),32.6%重分类为R1/2。
  • IASLC R(un)患者预后显著差于R0、但优于R1/2。
  • 校正细分N2描述符后,IASLC R0与R(un)的预后差异仍相似。

核心结论

  • 基于IASLC标准的详细R描述符联合细分N描述符可确保最佳分期,有助于pN2 NSCLC患者辅助治疗的合理决策。

研究设计与样本

  • 回顾性队列研究,纳入2004至2018年接受解剖性切除的1039例pN2 NSCLC患者。
  • 比较UICC标准与IASLC标准定义的R状态,采用Cox比例风险模型评估IASLC R描述符的预后意义。

主要发现

  • UICC标准下R0、R1、R2分别为91.1%、8.1%、0.8%;IASLC标准下R0、R(un)、R1/2分别为41.6%、20.4%、38%。
  • 206例(21.8%)从UICC R0重分类为IASLC R(un),主要因最高纵隔淋巴结受累(89.8%)。
  • 309例(32.6%)UICC R0因囊外扩展重分类为IASLC R1/2。
  • IASLC R(un)患者预后显著差于IASLC R0、但显著优于IASLC R1/2。
  • 多变量分析中,校正pN2a1、pN2a2、pN2b等细分N2描述符后,IASLC R0与R(un)的预后差异相似。

临床怎么用

  • 对pN2 NSCLC术后标本应采用IASLC R描述符进行更细致分类,以识别R(un)患者并指导辅助治疗决策。

局限性

  • 回顾性研究设计。
  • 单中心数据,外推性需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study aimed to validate the residual tumor (R) descriptors proposed by the International Association for the Study of Lung Cancer (IASLC) for patients with pathologic N2 (pN2) NSCLC. METHODS: We retrospectively reviewed the data of patients with pN2 NSCLC who underwent anatomical resection during the period 2004 to 2018. The R status classified using the Union for International Cancer Control (UICC) criteria was compared with that reassigned using the IASLC criteria. Survival analysis was performed using Cox proportional hazards models to assess the prognostic significance of IASLC R descriptors. RESULTS: Among 1039 patients, 91.1%, 8.1%, and 0.8% of the patients respectively received complete resection (R0), R1, and R2 defined using the UICC criteria, whereas 41.6%, 20.4%, and 38% respectively received R0, uncertain resection (R[un]), and R1/2 resection defined using the IASLC criteria. Furthermore, 206 patients (21.8%) were reclassified from having UICC R0 to having IASLC R(un) mainly owing to the highest mediastinal lymph node involvement (89.8%). Owing to extracapsular extension, 309 patients (32.6%) with UICC R0 were reclassified as having IASLC R1/2. Patients with IASLC R(un) had significantly worse and better prognosis than those with IASLC R0 and IASLC R1/2, respectively. In multivariable analysis, the prognostic difference between IASLC R0 and R(un) was similar after adjustment for subdivided N2 descriptors including pN2a1, pN2a2, and pN2b. CONCLUSIONS: Along with subdivided N descriptors, detailed R descriptors proposed on the basis of the IASLC criteria can ensure optimal staging, enabling the most appropriate decision-making on adjuvant therapy for patients with pN2 NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Yun JK, Lee GD, Choi S, et al. A Validation Study of the Recommended Change in Residual Tumor Descriptors Proposed by the International Association for the Study of Lung Cancer for Patients With pN2 NSCLC. J Thorac Oncol. 2021. PMID: 33607310. doi:10.1016/j.jtho.2021.01.1621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。